Bolt Biotherapeutics, Inc. Operating Income Loss

• Bolt Biotherapeutics, Inc. showed an increase of +50.6% in Operating Income Loss from 2024 to 2025.
• This data is from Bolt Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
• XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 6 years of available data (2020 to 2025), Bolt Biotherapeutics, Inc.'s Operating Income Loss has grown by 26.6%.
• Historical annual values: Fiscal year 2025: -$36.11 million | Fiscal year 2024: -$73.05 million | Fiscal year 2023: -$76.20 million | Fiscal year 2022: -$90.32 million | Fiscal year 2021: -$92.79 million | Fiscal year 2020: -$49.18 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026